These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768 [TBL] [Abstract][Full Text] [Related]
4. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222 [TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
7. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor. Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity Comparison of Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855 [TBL] [Abstract][Full Text] [Related]
9. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343 [TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of hitherto unknown brain meningioma detected on Parghane RV; Talole S; Basu S World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748 [TBL] [Abstract][Full Text] [Related]
13. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584 [TBL] [Abstract][Full Text] [Related]
14. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors. Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056 [TBL] [Abstract][Full Text] [Related]
16. Localization of Unknown Primary Site with Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957 [TBL] [Abstract][Full Text] [Related]
17. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Kjaer A; Knigge U Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100 [TBL] [Abstract][Full Text] [Related]
18. Safety and accuracy of Abongwa C; Mott S; Schafer B; McNeely P; Abusin G; O'Dorisio T; Zamba G; O'Dorisio MS; Menda Y Am J Nucl Med Mol Imaging; 2017; 7(5):228-235. PubMed ID: 29181270 [No Abstract] [Full Text] [Related]
19. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391 [TBL] [Abstract][Full Text] [Related]
20. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]